secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001785530-23-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics reports Q4 2022 net loss $11.9M; cash runway extended through Q4 2024
--------------------------------------------------------------------------------

- Net loss $11.9M for Q4 2022, compared to $17.9M in Q4 2021; full year net loss $53.8M (2021: $50.0M).
- Cash and equivalents $129.3M at Dec 31, 2022; company drew down full $40M term loan, extending runway through at least Q4 2024.
- Collaboration revenue $7.3M (Q4 2022) from Jazz licensing agreement; zero in prior year period.
- Phase 1/1b WTX-124 (IL-2) dose-escalation ongoing; interim data expected in Q4 2023.
- First patient dosed in Phase 1 WTX-330 (IL-12) trial in Feb 2023; WTX-712 (IL-21) nominated for preclinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553023000007/0001785530-23-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553023000007/howl-20230323.htm
  HTML page:      https://secwatch.observer/filing/0001785530-23-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer